BIRC7 anticorps (AA 1-265)

N° du produit ABIN7145211

Détail du produit anti-BIRC7 anticorps

Antigène: BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))

Épitope: AA 1-265

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BIRC7 est non-conjugé

Application: Western Blotting (WB), ELISA

Réactivité croisée: Humain

Purification: Antigen Affinity Purified

Immunogène: Recombinant Human Baculoviral IAP repeat-containing protein 7 protein (1-265AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:200-1:1000,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur BIRC7

Antigène: BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))

Autre désignation: BIRC7 (BIRC7 Produits)

Synonymes: anticorps KIAP, anticorps LIVIN, anticorps ML-IAP, anticorps MLIAP, anticorps RNF50, anticorps EIAP/XLX, anticorps XLX, anticorps kiap, anticorps livin, anticorps ml-iap, anticorps mliap, anticorps rnf50, anticorps xEIAP, anticorps RGD1562883, anticorps zgc:165605, anticorps E130019N06, anticorps Livin, anticorps birc7, anticorps bird7a, anticorps xEIAP/XLX, anticorps xlx, anticorps EIAP/XLX-B, anticorps birc7b, anticorps baculoviral IAP repeat containing 7, anticorps baculoviral IAP repeat-containing 7, anticorps baculoviral IAP repeat-containing 7 (livin), anticorps baculoviral IAP repeat containing 7 S homeolog, anticorps baculoviral IAP repeat containing 7 L homeolog, anticorps BIRC7, anticorps birc7, anticorps Birc7, anticorps birc7.S, anticorps birc7.L

Sujet:

Background: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing.

Aliases: Baculoviral IAP repeat containing 7 antibody, Baculoviral IAP repeat containing protein 7 antibody, Baculoviral IAP repeat-containing protein 7 antibody, BIRC 7 antibody, birc7 antibody, BIRC7_HUMAN antibody, KIAP antibody, Kidney inhibitor of apoptosis protein antibody, Livin antibody, Livin inhibitor of apotosis antibody, Melanoma inhibitor of apoptosis protein antibody, ML IAP antibody, ML-IAP antibody, MLIAP antibody, RING finger protein 50 antibody, RNF 50 antibody, RNF50 antibody

UniProt: Q96CA5